Kodiak Sciences Inc. KOD

KOD Company Overview

Kodiak Sciences Inc. is a U.S.-based biopharmaceutical company focused on developing therapeutics for retinal diseases and chronic eye disorders. The company operates within the biotechnology and ophthalmology industries, with a primary emphasis on therapies designed to improve durability, efficacy, and patient outcomes in diseases such as wet age-related macular degeneration (wet AMD), diabetic retinopathy, diabetic macular edema (DME), and retinal vein occlusion. Kodiak’s core business model centers on research, clinical development, and commercialization of proprietary ophthalmic biologics and drug delivery technologies.

The company’s principal strategic asset has been its antibody biopolymer conjugate (ABC) platform, which was designed to extend durability and improve retinal drug delivery. Kodiak became publicly traded after completing its initial public offering in 2018 and has focused heavily on advancing late-stage retinal disease programs. Historically, the company’s lead product candidate was tarcocimab tedromer, although development priorities have evolved following clinical trial outcomes and portfolio reassessments disclosed in public filings and investor communications. Kodiak’s positioning has been tied to its attempt to reduce treatment burden in retinal disease management through longer-lasting therapies.